Document is current

Article History

Received: 26 January 2021

Accepted: 1 November 2021

First Online: 6 December 2021

Declarations

:

: This study has received full ethics committee approval and protocol amendments approval from the Cambridge and Hertfordshire NHS Research Ethics Committee, IRAS Project ID 254507, REC ref: 19/EE/0046. Written informed consent will be sought at two stages from all participants; to be screened for eligibility and to participate.

: Not applicable

: Eduardo Cinosi, David Adam ,Ibrahim Aslan, Kieran Chillingsworth, Arun Enara, Tim Gale, Kabir Garg, Matt Garner, Robert Gordon, Natalie Hall, Nathan TM Huneke, , Sonay Kucukterzi-Ali, Joanne McCarthy, Daniel Meron, Deela Monji-Patel, Roisin Mooney, Megan Smith, David Wellsted, Solange Wyatt have no competing interests to declare.Prof. David S. Baldwin is a Medical Patron of Anxiety UK and was Clinical Advisor to the National Clinical Audit of Anxiety and Depression (2017-20). He receives an editorial fee from Wiley for his work with <i>Human Psychopharmacology</i>.Prof. Trevor W Robbins provides consultancy for Cambridge Cognition and receives royalties for CANTAB. He offers consultancy for Arcadia, Takeda, Cassava, Greenfield Bioventures. He has received research grants from Shionogi and GlaxoSmithKline. He is Editorial Honoraria for Springer, Nature and Elsevier.Nick Sireau is the chair and co-founder of the charity ORCHARD which focusses on developing treatments for patients suffering from obsessive–compulsive disorder (OCD). He is the director of the start-up Sirgartan that plans to work in the area of mental health. He is consultant for Biohaven on clinical trials in OCD. He is a member of the Trial Steering CommitteeProf. Naomi Fineberg reports in the past 3 years she has held research or networking grants from the ECNP, UK NIHR, EU H2020, MRC, University of Hertfordshire; accepted travel and/or hospitality expenses from the BAP, ECNP, RCPsych, CINP, International Forum of Mood and Anxiety Disorders, World Psychiatric Association, Indian Association for Biological Psychiatry, Sun; received payment from Taylor and Francis and Elsevier for editorial duties; accepted a paid speaking engagement in a webinar sponsored by Abbott. Previously, she has accepted paid speaking engagements in various industry supported symposia and have recruited patients for various industry-sponsored studies in the field of OCD treatment. She leads an NHS treatment service for OCD. She chairs an EU-funded COST Action into problematic internet usage. She holds Board membership for various registered charities linked to OCD. She gives expert advice on psychopharmacology to the UK MHRA. She has participated in a WHO working group focussing on diagnosis and classification of obsessive–compulsive or related disorders for the ICD-11.